Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Indonesia Pharmacon: Jurnal Farmasi Indonesia
Afifah Listiadewi
Universitas Airlangga
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
CLOVIBACTIN : STUDI LITERATUR ANTIBIOTIK BARU YANG DIHARAPKAN DAPAT MENGATASI RESISTENSI Wulida Nuril Fajriyah; Zamrotul Izzah; Eko Budi Koendhori; Afifah Listiadewi; Melisa Nur Diniah
Jurnal Farmasi Indonesia Vol 22 No 2 (2025): Jurnal Farmasi Indonesia
Publisher : Fakultas Farmasi Universitas Setia Budi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31001/jfi.v22i2.2717

Abstract

This review discusses about that Clovibactin is a new antibiotic isolated from soil samples in the state of North Carolina. Clovibactin contains eight depsipeptide residues consisting of a macrolactone ring and a linear tail. This antibiotic is active against gram-positive bacteria, including drug-resistant human pathogens such as Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant enterococci, dan Mycobacterium.tuberculosis. This review aims to assess the activity of clovibactin against Mycobacterium tuberculosis. Clovibactin works by inhibiting all cell wall biosynthesis reactions that consume lipid I, lipid II, lipid IIIwall teichoic acid or undecaprenyl-pyrophosphate (C55PP). Clovibactin showed no cytotoxicity to National Institute of Health/3T3 and HepG2 cells in mammals at a dose of 100 µg/mL. Clovibactin has bactericidal properties on gram-positive bacteria. Clovibactin has an MIC of 0.5-1 µg/mL on M.tuberculosis so it has good bactericidal efficacy with low toxicity.
Mechanism and Target Therapy of Rituximab in Systemic Lupus Erythematosus: Literature Review Afifah Listiadewi; Suharjono
Pharmacon: Jurnal Farmasi Indonesia Vol. 22 No. 1 (2025)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v22i1.8103

Abstract

The malignant condition known as lymphoma affects the lymphoid tissues, bone marrow, and blood. Between 2009 and 2013, the incidence rate of lymphoma in the United States was approximately 22 per 100,000 individuals. Hemolytic anemia, leukopenia, and thrombocytopenia are among the hematologic symptoms of systemic lupus erythematosus (SLE), a highly diverse disease. Rituximab (RTU) and other monoclonal antibodies that target β cells are used as off-label therapy for SLE. Rituximab is a human CD20-specific chimeric monoclonal antibody. Rituximab can be utilized as an alternate therapy for SLE in addition to providing treatment for lymphoma. Rituximab has demonstrated positive effects and potential as a treatment for SLE in several clinical trials. This study aims to elucidate the mechanism of action of rituximab as a therapeutic agent targeting β cells in patients with SLE. The methodology used in this study is a literature review. The literature retrieval and search strategies were conducted using electronic means. A literature review of seven periodicals was produced by employing keywords to retrieve scientific material using the Boolean approach. Rituximab depletes and inhibits the activation of β cells in individuals with systemic lupus erythematosus by binding to the Fc gamma IIβ receptor on both β cells and macrophages.
Co-Authors Eko Budi Koendhori, Eko Budi Melisa Nur Diniah Suharjono Wulida Nuril Fajriyah Zamrotul Izzah